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Summary Mast cells were shown to accumulate around the periphery of the invasive and metastatic rat
mammary adenocarcinoma (MTLn3), and histological evidence of mast cell degranulation was observed
during the later stages of this model. To assess the physiological role of mast cells in vivo we have used the
mast cell-stabilising compound FPL 55618 applied i.p. daily at 1 mg kg- for 23 days. Using groups of 12 rats
we have found that this compound inhibited tumour growth at the primary site by as much as 70% in most of
the treated animals compared with the control group which received equivalent volumes of saline. When the
drug treatment was stopped after 23 days, tumour growth of the test group accelerated over the next 7 days
and reached a similar tumour size to that of control animals. Histological studies of the tumour and
contiguous host tissue at day 24 of the experiment revealed numerous extra-tumoural mast cells often showing
signs of degranulation at several sites around the tumour periphery in the control animals. Such observations
were not seen in those animals receiving FPL 55618 where, in contrast to controls, numerous intact mast cells
were often seen within the tumour mass. Following cessation of the MC-stabilising treatment progressive mast
cell activation was evident within 2-4 days, primarily at the tumour periphery.
In vitro studies have shown that drug concentrations equivalent to five times the in vivo dose had no effect
on the proliferative rate or viability of the MTLn3 cells. Moreover, the proliferative rate of these cells in
culture was significantly increased when exposed to soluble mast cell products. Thus our data indicate that a
mast cell-stabilising compound has significant benefits in reducing tumour growth in vivo, an observation
which supports the concept that mast cell:tumour cell interactions are important for the growth and invasive
properties demonstrated by this model of breast carcinoma.
Invasion and metastasis are cardinal features of malignant
tumours and the complexity of these phenomena is well
recognised (Fidler & Hart, 1982; Liotta, 1984; Nicolson,
1988). Tumour cell interactions with the interstitial stroma or
specific host cells may be of prime importance in determining
invasive and metastatic behaviour (Yamada et al., 1985;
Woolley, 1984; Dabbous et al., 1986a). Stromal changes
including extensive collagen degradation have been observed,
and there is substantial evidence for the release of col-
lagenolytic enzymes by invasive tumour cells (Dabbous et al.,
1983; 1986a and b; Liotta et al., 1982; Woolley 1982). The
importance of host-tumour cell-cell interactions and the
potential participation of both tumour cells and adjacent
host cells in matrix degradation has been demonstrated by
numerous in vitro studies (Bauer et al., 1979; Biswas, 1982;
Dabbous et al., 1983; 1986a and b).
The presence of mast cells at the tumour-host junction of
several types of tumour has been recognised (Hartveit, 1981;
Hartveit et al., 1984; Parwaresch et al., 1985; Dabbous et al.,
1986a). Although it has been suggested that mast cells are
important in connective tissue diseases (Smyth & Gum, 1958;
Lewis & Austen, 1981) their functional role in tumour
behaviour has remained speculative and controverisal (Selye,
1965; Broom & Alexander, 1975a; Ionov, 1989). Our recent
observations of stromal lysis associated with mast cell de-
granulation at the tumour periphery of rat mammary
adenocarcinoma suggested that mast cells could contribute
directly to matrix degradation, either by the release of their
own proteinases or by modulation of the collagenolytic
activity of surrounding cells (Dabbous et al., 1986a, 1986b).
To determine the physiological role of mast cells in this
context we have treated experimental rats with the effective
mast cell-stabilising compound FPL 55618 and have
examined its effect on the development of the rat mammary
adenocarcinoma. We report here that the pharmacological
elimination of mast cell activity in vivo resulted in significant
inhibition of tumour growth, an observation supported by in
vitro studies which showed that soluble mast cell products
enhanced the proliferative rate of these tumour cells.
Materials and methods
Drugpreparation
The Fisons compound FPL 55618 [8-allyl-5-(3-methyl-
butyloxy) - 4 -oxo -8-prop-2-enyl4H-I-benzopyran- 2-carboxylic
acid] Na salt is a monochrome which is structurally related
to disodium cromoglycate. It is a mast cell stabiliser 87-times
more potent than the latter in the rat passive cutaneous
anaphylaxis test following intravenous administration. The
compound was progressed to man but was found, following
topical administration, to have only minimal activity against
human antigen challenge (Cairns, 1980; Suschitzky & Sheard,
1984). FPL 55618 was a generous gift from Dr Roy Eady,
Fisons plc, Loughborough, UK.
FPL 55618 was applied intraperitoneally daily at
1 mg kg-' body weight. It was prepared at 0.15 mg ml-' in
phosphate buffered saline, sterile filtered and stored at
- 20°C until utilised.
Tumour cells
MTLn3 clone was isolated from lung metastasis of rat mam-
mary adenocarcinoma 13762NF and was maintained in
Alpha-modified minimum essential medium (AMEM) con-
taining 10% heat-inactivated foetal calf serum (FCS) without
antibiotics as described previously (Neri & Nicolson 1981;
Neri et al., 1982). Trypsinisation, cell counts and single cell
suspensions of the tumour cells in Dulbecco's phosphate
buffered saline (DPBS) were prepared by a single individual
(LH) to ensure consistency.
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Animals and treatment
Pathogen-free, virgin female Fischer 344 rats were divided
into two groups: Group 1 control (n = 19); Group 2, FPL
55618 (n = 19). The animals were weighed, assigned numbers
for identification and i.p. injected with 1 ml of PBS or FPL
55618 for groups 1 and 2, respectively. Shortly after each rat
under anaesthetic received a 0.2 ml sub-cutaneous injection
of 5 x 105 MTLn3 tumour cells in the mammary fat pad.
Animals were treated with daily i.p. injections for 23 con-
secutive days and then left untreated for the duration of the
experiment. The tumour-bearing animals were examined
daily for the presence of mammary tumours and weighed
every 4 days. Animals were sacrificed as follows: (a) 12 rats
from each group 1 day after the final drug treatment (day
24), and (b) five rats each from Group I and Group II, 7
days after the last drug treatment (day 30).
Tumour growth
Tumours at the primary injection site were excised together
with smaller tumour deposits following macroscopic
examination at autopsy. The tumours were easily recognised,
freed from adjacent connective tissue, blotted dry and
weighed.
Statistical analysis
Significance of differences between treatment groups for
percentage of tumour burden were calculated using the
Scheffe F-test.
Histology
Animals from each group provided tumour specimens for
histological analysis. Each tumour was excised with attached
host tissue and was fixed for 2 h in 1.0%. formaldehyde and
0.25% glutaraldehyde in 0.1 M sodium cacodylate buffer
(pH 7.4) at 4°C, and rinsed in 0.15 M cacodylate buffer prior
to acetone dehydration. The specimens were embedded in
Immuno-bed (Polysciences, Warrington, PA) at 4°C and
3 ytm plastic sections were examined after staining for
naphthol-ASD-chloracetate esterase activity as decribed
previously (Bromley & Woolley, 1984) or acidified Toluidine
blue. Sections were also counter stained with 0.25% Azure
11-0.25% methylene Blue in 0.25% Borax.
Tumour cellproliferation
Tumour cells were plated out at 5.104 cellsml-' in 6-well
cluster dishes in DMEM-10% FCS for 24h. The medium
was changed to DMEM with and without FPL 55618 at
concentrations of 1 and 5 fig ml-' and the cells were
incubated for 3 days at 37'C in a water-saturated atmosphere
of 5% CO2 in air. Cells were detached by trypsinisation and
counted using a Coulter Counter.
Soluble mast cell products (MCP) were prepared from
purified rat peritoneal mast cells and Furth mouse masto-
cytoma cells as described previously (Dabbous et al., 1986a).
MCP in DMEM was adjusted to the equivalent of 106 mast
cellsml-' and used in the cell proliferation assay described
above. Similar concentrations of cells from the non-
metastatic MTLn2 rat tumour cell line and the human breast
carcinoma cell-line (8701 -BC) were extracted in an identical
manner as the mast cells to provide control and comparative
data.
Results
Rats injected with MTLn3 tumour cells developed palpable
tumours within 14-16 days in the control group receiving
daily PBS injections. By contrast, animals receiving daily
injections of FPL 55618 developed palpable tumours much
later. Both groups of animals appeared to have no adverse
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Figure 1 Body weight of the FPL-55618 (a) and saline-treated
(0) animals during the course of the experiment. Plots represent
mean values ± s.e.m.
side effects from the daily treatments as judged by regular
examination and a continued increase in body weight over
the first 15 days of the experiment (Figure 1). The tumour
burden of each animal was assessed by autopsy at day 24 by
excising and weighing all visible tumour tissue. Although in
most cases each animal had one major tumour deposit at the
site of tumour cell injection, several animals had secondary
nodular deposits associated with the primary growth.
The tumour weights for each animal are presented in Table
I which shows the mean values for the control and FPL
55618-treated animals as 4.93 and 1.62, respectively. This
represents almost a 70% inhibition of tumour growth.
Although tumour sizes were of much the same order in most
animals of the group there were a few exceptions, but the
difference in tumour weights of the two groups was statisti-
cally significant (P <0.0001). When the drug treatment (i.p.
injections) were stopped after 23 days, tumour growth of the
test group accelerated over the next 7 days and reached a
similar tumour size to that of control animals (Table II). This
'rebound' effect was an impressive response to withdrawal of
the mast cell stabiliser, and was a consistent observation in
three separate experiments.
Careful examination at autopsy on day 24 showed that
three animals in the control group had developed metastatic
lesions in the axillary lymph node and abdominal region,
while no visible metastasis was detected in the test group
during the drug administration. Seven days after termination
of the drug treatment metastatic deposits were observed in
the axillary lymph node in one animal from each group.
Although histologic examination showed no evidence of lung
colonisation by spontaneous metastasis after 24 days of
tumour growth, all animals showed lungs with edematous
widening of alveolar septa (data not shown). In this tumour
system, additional time is usually required for gross lung
metastasis to be evident (Neri et al., 1982).
The mast cell-staining techniques of chloroacetate esterase
or acidified toluidine blue were applied to 3 ptm sections of
tumour specimens fixed at day 24 from both control and
FPL 55618-treated animals. Specimens from the control
group showed the presence of many mast cells at the tumour
periphery with very few intratumoural mast cells. Moreover,
small groups of mast cells at local, peripheral sites of the
tumour showed clear evidence of activation and degranula-
tion (Figures 2d, 2e) which was not evident in stromal mast
cells remote from the tumour junctions. In contrast the
tumour specimens from the FPL 55618-treated animals did
not show obvious signs of mast cell degranulation, there were
many more intratumoural mast cells, and the stromal matrix
FPL
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Table I Tumour weights excised at day 24
Group
DPBS
Rat
no.
2
3
4
5
6
7
8
9
10
FPL 55618 1
2
3
4
5
6
7
8
9
10
Animal wt.
(g)
172
157
132
145
143
167
148
148
160
161
145
145
171
163
168
162
177
165
173
143
showed little signs of disruption or lysis (Figures 2a, 2b).
Examination of specimens from animals killed at 1, 2, 3 and
4 days after cessation of drug treatment showed evidence for
a depletion in granule content of most mast cells associated
with the tumour approximately 2 to 3 days after drug with-
drawal (Figures 2c, 2f), and thereafter the mast cell observa-
tions were similar to those seen for control animals. Thus the
histological observations provide some evidence that the mast
cell-stabilising compound was effective during its administra-
tion for 23 days.
Since one explanation for the inhibition of tumour growth
was the possible cytotoxic effect of FPL 55618 on the MTLn3
cells, the viability and growth rate of MTLn3 cells in the
presence and absence of the drug in vitro was examined.
Drug concentrations equivalent to five times the in vivo dose
had no direct effect on the proliferative rate or viability of
the MTLn3 cells (Figure 3).
The ability of mast cells to stimulate the proliferative rate
of MTLn3 cells in vitro is shown in Figure 4. Tumour cells
incubated with soluble mast cell products of either rat or
mouse origin showed an increased rate of proliferation. By
contrast the addition of similarly prepared extracts derived
from rat and human tumour cells produced no increase in
the proliferative rate. Moreover, the MCP-stimulation of
proliferation was found to be concentration dependent
(Figure 4). Such in vitro observations suggest that direct mast
cell:tumour cell interactions could contribute significantly to
the requirements for tumour growth as observed in vivo.
Discussion
The importance of mast cells in local homeostasis,
inflammation and tumour surveillance is supported by many
Total tumour
wt. (g)
8.26
5.68
3.23
5.83
6.02
4.10
6.50
3.07
2.21
4.36
2.23
2.67
0.31
1.30
0.97
1.60
1.20
1.12
2.10
2.70
Tumour weight
(g) (mean ± s.e.m.)
4.93 ± 0.59
1.62± 0.25
P <0.0001
studies (Lewis & Austen, 1981; Parwaresch et al., 1985;
Roche, 1986; Serafin & Austen, 1987), and the association of
mast cells with a variety of tumours has long been recognised
(Ehrlich, 1879; Hartveit, 1981; Hartveit et al., 1984; Roche,
1985, 1986; Dabbous et al., 1986a). Despite many histo-
pathological reports of mast cells at sites of tumour invasion
the functional significance of mast cells in tumour biology
remains obscure. In many cases the presence of mast cells has
been interpreted as an immunological anti-tumour response
(Csaba et al., 1961; Graham & Graham, 1966; Parwaresch et
al., 1985), but recent studies have supported a more direct
interaction with tumour cells, especially interactions which
facilitate tumour growth (Nordlund & Askenase, 1983;
Roche, 1985; Norrby, 1985).
Previous studies have used mast cell-stabilising compounds
to examine the relative contribution of these cells to tumour
development (Nordlund & Askenase, 1983; Roche, 1986) and
have generally concluded that tumour growth was signifi-
cantly reduced. The present study has demonstrated that
prolonged exposure (23 days) to FPL 55618 resulted in
inhibition of tumour growth in vivo by approximately 70%
that of controls, but once this treatment was withdrawn a
rapid acceleration of tumour growth was observed. The histo-
logical studies indicate that FPL 55618 was an effective
stabiliser of mast cell function since little evidence of deg-
ranulation was observed in those animals receiving the drug.
Indeed, the presence of intratumoural mast cells is very
unusual in this model (Dabbous et al., 1986a) yet these were
commonly seen in the drug-treated tumour specimens. The
rapid tumour growth that followed withdrawal of the drug
was shown histologically to be associated with an increase in
mast cell activation and degranulation. One striking observa-
tion was the granule depletion of intratumoural mast cells
within 2-3 days of withholding FPL 55618 treatment, subse-
Table II Tumour weights excised at day 31 (24 + 7)
Rat Animal wt. Total tumour Tumour weight
Group no. (g) wt. (g) (g) (mean ± s.e.m.)
DPBS 11 145 5.11 4.22 0.44
12 169 2.89
13 171 4.64
14 169 3.50
15 182 4.95
FPL 55618 11 181 7.41 5.53 1.13
12 163 5.67
13 166 1.51
14 138 5.17
15 161 7.90876 M.Kh. DABBOUS
Figure 2 Comparative histology of the tumour periphery of rat mammary adenocarcinoma in control and FPL-55618-treated
animals. a and b, photomicrographs showing intact and intratumoural mast cells in drug-treated animals at day 24. d and e,
photomicrographs showing mast cell degranulation (arrows) at the tumour periphery of control animals at day 24. c and f,
photomicrographs showing mast cell granule depletion in specimens excised 2 and 4-days, respectively, after cesssation of
FPL-55618 treatment. Toluidine blue staining. Bars = 501tm for a and d, and 20Jim for b,c,e and f.
quently giving rise to negligible mast cells within the tumour
and signs of degranulation by those surrounding the growing
tumour. Such observations suggest that the accelerated
growth of the tumour reflects a 'rebound' effect whereby
mast cells, freed from their pharmacological restraint, contri-
bute a local and concentrated supply of growth factors/
mediators.
The association of mast cell activation with localised mat-
rix dissolution has been noted (Norrby & Enestrom, 1984,
Dabbous et al., 1986a,b) and was much in evidence in the
present study. Mast cells contain the potent serine pro-
teinases tryptase and chymase (Schwartz, 1989) which are
functional at neutral pH. Although much is known about the
physicochemical properties of these enzymes, relatively little
is known about their natural protein substrates. However
tryptase is reported to activate pro-stromelysin (MMP-3)
with its subsequent activation of procollagenase (Gruber et
al., 1989) and resultant collagenolysis. Moreover, mast cell
products were shown to stimulate the production of col-
lagenase from both fibroblasts and rat tumour cells in vitro
and also to activate the collagenase precursor (Yoffe et al.,
1984; Dabbous et al., 1986a).
The stimuli that induce mast cell degranulation have been
the subject of many reviews which usually focus on IgE-
mediated-immune reactions. IgE-antibodies specific to
tumour antigens have been reported for specific animal
tumours (Sweeney & Seibel, 1973; Bartholomaeus et al.,
1974; Bartholomaeus & Keast, 1972; Broom & Alexander,
1975b), but as yet it is uncertain whether such antibodies are
formed in the rat 13762NF mammary adenocarcinoma. In
addition to IgE-mediated activation of mast cells it is now
apparent that other triggering mechanisms exist such as com-
plement, neurohormones and factors from lymphocytes,
neutrophils, macrophages and tumour cells (Scott, 1963;MAST CELLS AND TUMOUR GROWTH 877
FPL 55618 (ig ml-')
Figure 3 Effect of FPL-55618 on tumour cell (MTLn3) prolifera-
tion (and viability) in vitro. Drug concentrations of 1 and
5 fig ml- had no significant effect on tumour cell proliferation
after 3 days compared to control cultures. *, 5.104cells ml' at
time zero. Values are mean ± s.e.m. for triplicate assays.
Roche, 1985; Baeza et al., 1989). The tumour periphery of
the rat mammary adenocarcinoma in this study often con-
tained inflammatory cells, viz. T-lymphocytes, macrophages
and neutrophils, but usually such cells were confined to
microenvironmental locations. Thus the cellular composition
at the tumour periphery was quite variable, observations
which possibly reflect different aspects of the host response,
but also provide a variable source of potential mast cell-
triggering factors. Whatever these factors are, our histo-
logical findings indicate that mast cell degranulation occurs
at the tumour periphery of this model, and that a daily
administration of FPL 55618 appears to be an effective
stabiliser of these cells.
Soluble mast cell products were shown to stimulate pro-
liferation of the MTLn3 cells in a manner similar to that
reported for rat sarcomas and squamous carcinomas, where
heparin was identified as a growth factor (Roche, 1985,
1986). Mast cell heparin has also been implicated in tumour-
associated angiogenesis where it stimulates endothelial cell
proliferation and migration (Azizkhan et al., 1980), and
recent in vivo studies with mast cell-deficient mice have de-
monstrated a role for mast cells in tumour angiogenesis
(Starkey et al., 1988). Since continued tumour growth is
dependent upon the ingrowth and supply of new vasculature
(Kessler et al., 1976) it is possible that the inhibition of
tumour growth reported here with FPL 55618 is explained
not only by the prevention of a direct stimulation of tumour
cell proliferation, but also by a reduction in the extent of
neovascularisation. At present the relative contribution of
these two aspects to tumour growth are unknown, as indeed
are other indirect mechanisms involving lymphocytes, macro-
phages and fibroblasts - all cells which may be 'activated' by
mast cell mediators. Histamine is also a potential stimulus
for tumour growth (Bartholeyns & Bouclier, 1984; Norrby,
1985), but it seems likely that several other mast cell growth
0 2 4 6 8 1 0 1 2
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Figure 4 Stimulatory effect of soluble mast cell products on
tumour cell (MTLn3) proliferation in vitro. 5.104cells ml' were
plated out at time zero (0) and subsequently exposed to 10%
(v/v) rat (R.MCP) and mouse mast cell products (M.MCP), and
similar soluble extracts from rat MTLn2 tumour cells (MTLn2)
and human breast carcinoma cells (8701-BC), all equivalent to
1.I05 cells ml ', for 3 days. MCP effects were also examined at 20
and 30% (v/v) concentrations. Values are mean ± s.e.m. for trip-
licate assays. *P<0.002, **P<0.0002, Student's t-test.
factors such as granulocyte/macrophage colony stimulating
factor (GM-CSF), interleukin-3 and other cytokines
(Wodnar-Filipowicz et al., 1989; Gordon et al., 1990) may
contribute to the behaviour of MTLn3 cells at the tumour-
host junction.
The tumour:host interface or 'invasion zone' of the rat
mammary adenocarcinoma is variable with regard to the type
and relative numbers of specific host cells, but mast cells are
always conspicuous. Where mast cell degranulation was
observed it was often associated with lysis of stromal connec-
tive tissue, possibly as a consequence of mast cell enzymes or
the stimulation and activation of collagenolytic enzymes by
neighbouring cells (Dabbous et al., 1986a,b). Such activities,
together with the production of growth factors and localised
oedema would promote the disruption of homeostasis and
could well favour tumour growth and invasion. The reduc-
tion in tumour growth effected by the mast cell-stabilising
compound FPL 55618 supports the hypothesis that local
mast cell activation at the tumour peripherpy contributes
significantly to tumour growth and development.
This work was supported by USPHS Grants CA-25617, CA-44352
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